[Development of hematopoietic stem cell-targeted gene therapy]

Area of Science:

• Biotechnology
• Hematology
• Genetic Medicine

Background:

• Hematopoietic stem cell (HSC) gene therapy shows curative potential for genetic blood diseases.
• HSCs possess self-renewal and multipotency, enabling lifelong cures via single treatments.
• Autologous HSC gene therapy, using lentiviral gene addition or editing, is donor-independent.

Purpose of the Study:

• To address the complexity and high cost of current ex vivo HSC gene therapy.
• To develop in vivo HSC gene therapy for direct delivery of genetic tools to bone marrow HSCs.

Main Methods:

• Ex vivo gene therapy involves harvesting, genetically modifying, and re-infusing patient HSCs.
• In vivo gene therapy research focuses on direct administration of gene therapy tools into bone marrow.

Main Results:

• Ex vivo HSC gene therapy has demonstrated efficacy in clinical trials.
• In vivo approaches are under development to overcome limitations of ex vivo methods.

Conclusions:

• In vivo HSC gene therapy represents a promising strategy to simplify treatment delivery and reduce costs.
• Direct delivery of gene therapy to HSCs could broaden access to curative treatments for genetic blood disorders.